• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

迈向将粪便免疫化学检测与结直肠癌筛查中的肠道微生物组相结合的第一步。

First steps towards combining faecal immunochemical testing with the gut microbiome in colorectal cancer screening.

机构信息

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

出版信息

United European Gastroenterol J. 2020 Apr;8(3):293-302. doi: 10.1177/2050640619890732. Epub 2019 Dec 19.

DOI:10.1177/2050640619890732
PMID:32213018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7184657/
Abstract

OBJECTIVES

Many countries use faecal immunochemical testing (FIT) to screen for colorectal cancer. There is increasing evidence that faecal microbiota play a crucial role in colorectal cancer carcinogenesis. We assessed the possibility of measuring faecal microbial features in FIT as potential future biomarkers in colorectal cancer screening.

METHODS

Bacterial stability over time and the possibility of bacterial contamination were evaluated using quantitative polymerase chain reaction analysis. Positive FIT samples ( = 200) of an average-risk screening cohort were subsequently analysed for universal 16S, and bacteria (), (), and () by qPCR. The results were compared with colonoscopy findings.

RESULTS

Faecal microbiota in FIT were stably measured up to six days for ( = 0.53), ( = 0.30), (p = 0.05) and ( = 0.62). Overall presence of bacterial contamination in FIT controls was low. Total bacterial load (i.e. 16S) was significantly higher in patients with colorectal cancer and high-grade dysplasia ( = 0.006). For the individual bacteria tested, no association was found with colonic lesions.

CONCLUSIONS

These results show that the faecal microbial content can be measured in FIT samples and remains stable for six days. Total bacterial load was higher in colorectal cancer and high-grade dysplasia. These results pave the way for further research to determine the potential role of microbiota assessment in FIT screening.

摘要

目的

许多国家使用粪便免疫化学检测（FIT）筛查结直肠癌。越来越多的证据表明，粪便微生物群在结直肠癌的发生中起着至关重要的作用。我们评估了在 FIT 中测量粪便微生物特征作为结直肠癌筛查潜在未来生物标志物的可能性。

方法

使用定量聚合酶链反应分析评估粪便中细菌随时间的稳定性和细菌污染的可能性。随后对平均风险筛查队列中的阳性 FIT 样本（ = 200）进行了通用 16S 分析，并通过 qPCR 分析了细菌（）、（）、（）和 （）。将结果与结肠镜检查结果进行比较。

结果

FIT 中的粪便微生物在六天内稳定测量，（ = 0.53）、 （ = 0.30）、 （p = 0.05）和 （ = 0.62）。FIT 对照中总体细菌污染的存在率较低。结直肠癌和高级别异型增生患者的总细菌负荷（即 16S）明显更高（ = 0.006）。对于测试的单个细菌，与结肠病变没有关联。

结论

这些结果表明，粪便微生物含量可在 FIT 样本中测量，并且在六天内保持稳定。结直肠癌和高级别异型增生患者的总细菌负荷更高。这些结果为进一步研究确定微生物评估在 FIT 筛查中的潜在作用铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/d766a945846e/10.1177_2050640619890732-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/0678e9ba2692/10.1177_2050640619890732-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/6c92d3af10e4/10.1177_2050640619890732-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/beee45a87aa8/10.1177_2050640619890732-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/09fc3c757450/10.1177_2050640619890732-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/f86cde2fbdb3/10.1177_2050640619890732-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/d766a945846e/10.1177_2050640619890732-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/0678e9ba2692/10.1177_2050640619890732-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/6c92d3af10e4/10.1177_2050640619890732-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/beee45a87aa8/10.1177_2050640619890732-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/09fc3c757450/10.1177_2050640619890732-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/f86cde2fbdb3/10.1177_2050640619890732-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad1/7184657/d766a945846e/10.1177_2050640619890732-fig6.jpg

相似文献

1
First steps towards combining faecal immunochemical testing with the gut microbiome in colorectal cancer screening.迈向将粪便免疫化学检测与结直肠癌筛查中的肠道微生物组相结合的第一步。
United European Gastroenterol J. 2020 Apr;8(3):293-302. doi: 10.1177/2050640619890732. Epub 2019 Dec 19.
2
Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients.检测挪威结直肠癌患者粪便和结肠组织中的具核梭杆菌。
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1367-1376. doi: 10.1007/s10096-019-03562-7. Epub 2019 Apr 25.
3
Enhancing Colorectal Cancer Screening with Droplet Digital PCR Analysis of Fusobacterium nucleatum in Fecal Immunochemical Test Samples.粪便免疫化学检测样本中具核梭杆菌的液滴数字 PCR 分析增强结直肠癌筛查。
Cancer Prev Res (Phila). 2024 Oct 1;17(10):471-479. doi: 10.1158/1940-6207.CAPR-23-0331.
4
The Role of Fecal and as Early Diagnostic Markers of Colorectal Cancer.粪便 和 的作用：结直肠癌的早期诊断标志物。
Dis Markers. 2021 Nov 22;2021:1171239. doi: 10.1155/2021/1171239. eCollection 2021.
5
Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer.微小帕毛单胞菌作为结直肠癌的一种潜在无侵犯性粪便生物标志物。
Sci Rep. 2020 Sep 17;10(1):15250. doi: 10.1038/s41598-020-72132-1.
6
Comparison of bacterial quantities in left and right colon biopsies and faeces.比较左、右结肠活检组织和粪便中的细菌数量。
World J Gastroenterol. 2012 Aug 28;18(32):4404-11. doi: 10.3748/wjg.v18.i32.4404.
7
Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies.粪便共生梭状芽孢杆菌用于非侵入性检测早期和晚期结直肠癌：检测和验证研究。
EBioMedicine. 2017 Nov;25:32-40. doi: 10.1016/j.ebiom.2017.10.005. Epub 2017 Oct 4.
8
Aspirin Reduces Colorectal Tumor Development in Mice and Gut Microbes Reduce its Bioavailability and Chemopreventive Effects.阿司匹林可降低小鼠结直肠肿瘤的发生，肠道微生物会降低其生物利用度和化学预防作用。
Gastroenterology. 2020 Sep;159(3):969-983.e4. doi: 10.1053/j.gastro.2020.05.004. Epub 2020 May 6.
9
Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer.炎症性肠病和结直肠癌患者肠道黏膜中普拉梭菌菌群I和菌群II丰度的变化
Inflamm Bowel Dis. 2016 Jan;22(1):28-41. doi: 10.1097/MIB.0000000000000590.
10
Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy.对超过 2000 份英国国民保健署肠癌筛查计划样本的微生物组分析显示，有可能提高筛查准确性。
Clin Cancer Res. 2021 Apr 15;27(8):2246-2254. doi: 10.1158/1078-0432.CCR-20-3807. Epub 2021 Mar 3.

引用本文的文献

1
Fecal microbiomes from screening sampling tubes are stable despite varying sampling and storage conditions.尽管采样和储存条件不同，但筛查采样管中的粪便微生物群是稳定的。
Sci Rep. 2025 Jul 24;15(1):26951. doi: 10.1038/s41598-025-12506-5.
2
Cracking the Code of Colorectal Cancer Screening: An Overview With a Focus on Current and Emerging Screening Methods.破解结直肠癌筛查密码：聚焦当前及新兴筛查方法的概述
Cureus. 2025 May 24;17(5):e84724. doi: 10.7759/cureus.84724. eCollection 2025 May.
3
Analysis of serum S100A12, soluble advanced glycation end products receptor, and gut microbiome in elderly patients with colorectal cancer.

本文引用的文献

1
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer.基于粪便宏基因组的荟萃分析揭示了与结直肠癌具有特异性的全球微生物特征。
Nat Med. 2019 Apr;25(4):679-689. doi: 10.1038/s41591-019-0406-6. Epub 2019 Apr 1.
2
Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps: A Systematic Review and Meta-analysis.粪便免疫化学试验检测结直肠癌和高级腺瘤的性能特征：系统评价和荟萃分析。
Ann Intern Med. 2019 Mar 5;170(5):319-329. doi: 10.7326/M18-2390. Epub 2019 Feb 26.
3
A widely used sampling device in colorectal cancer screening programmes allows for large-scale microbiome studies.
老年结直肠癌患者血清S100A12、可溶性晚期糖基化终产物受体及肠道微生物群分析
World J Gastrointest Oncol. 2025 Jun 15;17(6):106393. doi: 10.4251/wjgo.v17.i6.106393.
4
Fecal occult blood affects intestinal microbial community structure in colorectal cancer.粪便潜血影响结直肠癌患者的肠道微生物群落结构。
BMC Microbiol. 2025 Jan 20;25(1):34. doi: 10.1186/s12866-024-03721-7.
5
The use of non-invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance.非侵入性粪便检测用于验证幽门螺杆菌根除和克拉霉素耐药性。
United European Gastroenterol J. 2023 Nov;11(9):894-903. doi: 10.1002/ueg2.12473. Epub 2023 Oct 18.
6
Using fecal immmunochemical cartridges for gut microbiome analysis within a colorectal cancer screening program.在结直肠癌筛查项目中使用粪便免疫化学检测试剂盒进行肠道微生物组分析。
Gut Microbes. 2023 Jan-Dec;15(1):2176119. doi: 10.1080/19490976.2023.2176119.
7
Evaluating the predictive performance of gut microbiota for the early-stage colorectal cancer.评估肠道微生物群对早期结直肠癌的预测性能。
BMC Gastroenterol. 2022 Dec 12;22(1):514. doi: 10.1186/s12876-022-02599-x.
8
Microbiome and Colorectal Cancer Management.微生物组与结直肠癌管理
Cureus. 2022 Oct 26;14(10):e30720. doi: 10.7759/cureus.30720. eCollection 2022 Oct.
9
Correlation between Olive Oil Intake and Gut Microbiota in Colorectal Cancer Prevention.橄榄油摄入与结直肠癌预防中的肠道微生物群的相关性。
Nutrients. 2022 Sep 10;14(18):3749. doi: 10.3390/nu14183749.
10
Detection of Fusobacterium nucleatum DNA in primary care patient stool samples does not predict progression of colorectal neoplasia.在初级保健患者粪便样本中检测到具核梭杆菌 DNA 并不预示结直肠肿瘤的进展。
PLoS One. 2022 Jun 3;17(6):e0269541. doi: 10.1371/journal.pone.0269541. eCollection 2022.
一种在结直肠癌筛查项目中广泛使用的采样装置有助于开展大规模微生物组研究。
Gut. 2019 Sep;68(9):1723-1725. doi: 10.1136/gutjnl-2018-316225. Epub 2018 Sep 21.
4
The role of the microbiome in cancer development and therapy.微生物群落在癌症发展和治疗中的作用。
CA Cancer J Clin. 2017 Jul 8;67(4):326-344. doi: 10.3322/caac.21398. Epub 2017 May 8.
5
Comparison of Collection Methods for Fecal Samples in Microbiome Studies.微生物组研究中粪便样本采集方法的比较
Am J Epidemiol. 2017 Jan 15;185(2):115-123. doi: 10.1093/aje/kww177. Epub 2016 Dec 16.
6
DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model.粪便免疫化学检测的 DNA 可以替代粪便，用于基于微生物组的模型检测结肠病变。
Microbiome. 2016 Nov 14;4(1):59. doi: 10.1186/s40168-016-0205-y.
7
Fecal Bacteria Act as Novel Biomarkers for Noninvasive Diagnosis of Colorectal Cancer.粪便细菌可作为结直肠癌无创诊断的新型生物标志物。
Clin Cancer Res. 2017 Apr 15;23(8):2061-2070. doi: 10.1158/1078-0432.CCR-16-1599. Epub 2016 Oct 3.
8
A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening.基于人群的结直肠癌筛查中两种粪便免疫化学检测的随机比较。
Gut. 2017 Nov;66(11):1975-1982. doi: 10.1136/gutjnl-2016-311819. Epub 2016 Aug 9.
9
Colorectal cancer.结直肠癌。
Nat Rev Dis Primers. 2015 Nov 5;1:15065. doi: 10.1038/nrdp.2015.65.
10
Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions.基于微生物群的模型提高了粪便免疫化学检测结肠病变的灵敏度。
Genome Med. 2016 Apr 6;8(1):37. doi: 10.1186/s13073-016-0290-3.